Anorexia Nervosa is a serious illness and relapse rates are high. We have shown that behavioral routines get stuck/entrenched. Our newest research, Relapse Prevention and Changing Habits (REACH+) for Anorexia Nervosa, aims to help patients minimize unhelpful routines and develop more healthful recovery-oriented behavior. Participants will complete initial…
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three-arm clinical trial of immunosuppressive therapy for children with acute liver failure. This is a double-blind study, so the study doctors and participants will not know to which arm the participants are assigned. The study will determine if corticosteroids or equine anti-…
The purpose of this research study is to determine if an investigational drug, VS-01, will help in the treatment of acute-on-chronic liver failure (ACLF) compared to supportive care (standard of therapy). ACLF is a potentially life-threatening condition characterized by a group of signs that occur together (syndrome) in patients with a late stage of…
People with bulimia nervosa engage in risky behaviors more often than people without this disorder. We are researching the neurobiological underpinnings of risky decision-making in bulimia nervosa. As a participant in this study, you would: (1) complete a series of questionnaires and interviews, (2) complete an MRI scan (no radiation), and (3) complete…
People with bulimia nervosa engage in risky behaviors more often than people without this disorder. We are researching the neurobiological underpinnings of risky decision-making in bulimia nervosa. As a participant in this study, your teen would: (1) complete a series of questionnaires and interviews, (2) complete an MRI scan (no radiation), and (3)…
The purpose of this study is to evaluate the efficacy and safety of ION-682884 given for 24 months in patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN) also known as Familial Amyloid Polyneuropathy (FAP), and determine if it can help people with mild or moderate polyneuropathy. To be in this study you must have FAP and be…
HELIOS-A is a global Phase 3 randomized, open-label study designed to evaluate the safety and efficacy of ALN-TTRSC02 in adult patients with hATTR amyloidosis experiencing neurologic symptoms brought on by the disease. The study will also evaluate any changes in quality of life experienced by study participants. ALN-TTRSC02 utilizes the mechanism of RNA…